Dr. Pini Tsukerman is an immunologist by training and an expert in the field of novel immune therapies. Pini co-founded Nectin Therapeutics, built the pipeline, and led all scientific activities for the company: Establishment of the R&D department, building the IP portfolio, negotiating, and managing CRO and CDMO activities, and supporting capital raising. As the company matured, built the development strategy, diversifying and prioritizing the pipeline to include immune-checkpoint inhibitors, CAR-T/NK drivers, and ADCs bringing all programs to IND-enabling readiness, and successfully developing the leading project (NTX1088), from idea to clinical development.